Verdiva Bio
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Verdiva Bio has raised €399M across 1 funding round from 7 investors, most recently a Series A round in Jan 2025. Based in London, UK; active in Healthtech. Data as of 28 Oct 2026.
London, UKverdivabio.com ↗
Total raised
€399M
€398,874,224
Funding rounds
1
Investors
7
distinct backers
Active since
2025-01
latest 2025-01
Funding by year
EUR raised per yearVerdiva Bio — funding by year — interactive chart.
Data table
| Verdiva Bio — funding by year | |
|---|---|
| 2025 | €399M |
Signals
High confidenceRaise-next likelihood59
base rate 44% for Series A
- ▲ In typical raise window
- ▼ Low backer re-investment
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-01-10 | Series A | €399M | Forbion,General Atlantic,Lilly Asia Ventures,Logos Capital,LYFE Capital,OrbiMed+1 more | View deal → |